Connect with us

TRENDING

Tetra Bio Pharma Inc (OTCMKTS:TBPMF)’s Subsidiary Submits OTC DIN Applications To Treat Hemorrhoids, Joint And Muscle Pains, And Offer Relief To Aches

Published

on

Tetra Bio Pharma Inc (OTCMKTS:TBPMF)’s wholly-owned subsidiary – Tetra Natural Health, has submitted applications to Health Canada. The first OTC DIN application submitted on November 15, 2019, is to offer treatment for hemorrhoids. Its second application submitted on November 26, 2019, is to provide relief to patients suffering from joint and muscle pains related to sprains, bruises, strains, lumbago, backache, rheumatic pain, arthritis pain, and pain in ligaments and tendons. It also offers temporary relief to aches.

Self-care therapies

The OTC (over the counter) product line developed by Tetra comprises beta-caryophyllene. It is developed to offer self-care therapies to the patients and pharmacists by working directly on the CB2 receptors. The company plans to introduce these OTC pain relief products to get a pie of the OTC market, which is estimated at $19 billion. CRO and Chief Executive Officer of Tetra Bio-pharma, Dr. Guy Chamberland, said the company is focused on bringing proven therapies to the patients.

Expects a commercial launch in 2020

Tetra plans to launch OTC pain relief medicines commercially in early 2020 in the pharma retail outlets of Canada. The company is in negotiations with several firms to distribute and sell the products. It also plans to launch these products in the US next year. Tetra is applying for an NDC (National Drug Code) with the US FDA and negotiating with prospective bidders for contract manufacturing in the US.

Resumes clinical trial in cancer patients

With the nod of the US FDA, Tetra resumed clinical trial of (the previously halted) Plenitude in patients who have cancer in advanced stages. The company conducts the clinical trial for QIXLEEF to treat uncontrolled pain in cancer patients. FDA gave the nod after reviewing the quality profile of Tetra that includes mycotoxin quality information and on confirming that adequate safety measures are in place to safeguard the patients. Tetra would quickly enroll patients for its clinical trial.

Chamberland said the company is pleased to get FDA nod to proceed with the clinical trial of Plenitude. He said the company would launch the clinical trial in the coming days on seventy-eight adult patients. During the four-week trial, Tetra would evaluate the efficacy and safety of the inhaled PPP001 in cancer patients suffering from uncontrolled pain.

Business

Investing in the Age of Coronavirus (INO, APT, CODX, SGMD, IBIO, AYTU)

Published

on

The market is crashing almost every day right now. If you own the SPY, or a basket of large-cap leadership stocks that have defined this bull market for years, you’re getting destroyed over the past three weeks.

But there is an answer. A small group of stocks has been rallying precisely because of the impact of this terrible pandemic outbreak. The stocks in this group are driven by one of two core themes: either they represent companies vying to help solve the crisis, or they have operations that will be positively impacted by the behavioral adjustments that the outbreak is causing.

We have compiled a list of some of the most essential versions of these themes. Two of them are trying to help solve it medically (INO, IBIO). Two of them are working to supply us with the tools to weather it (CODX, APT). And one of them is primed to benefit from how people are being changed by coping with it (SGMD).

We will take a closer look at each of them in turn: Inovio Pharmaceuticals Inc (NASDAQ:INO), Alpha Pro Tech, Ltd. (NYSEAMERICAN:APT), Co-Diagnostics Inc (NASDAQ:CODX), Sugarmade Inc (OTCMKTS:SGMD), Ibio Inc (NYSEAMERICAN:IBIO), and Aytu Bioscience Inc (NASDAQ:AYTU).

 

Inovio Pharmaceuticals Inc (NASDAQ:INO) trumpets itself as a clinical stage biopharmaceutical company that develops active DNA immunotherapies and vaccines to prevent and treat cancers and infectious diseases.

The company is working on a vaccine for the novel coronavirus disease. In that vein, the company recently announced that it was accelerating the timeline for its experimental COVID-19 vaccine, INO-4800, and expects to begin a phase 1 study in humans in April.

This isn’t new for INO. At this point, the company is actually the only name out there with a vaccine for preventing a coronavirus in phase 2 testing, although the targeted disease, in this case, is MERS rather than COVID-19. But that still represents a meaningful edge in the all-important race now confronting the world.

The company’s lead candidate, though, is VGX-3100. Inovio expects to report preliminary results later this year from a late-stage study of the immunotherapy in treating cervical high-grade squamous intraepithelial lesions (HSIL) caused by human papillomavirus (HPV). The biotech is also conducting phase 2 studies of VGX-3100 for treating vulvar HSIL and anal HSIL.

Its SynCon immunotherapy design has the ability to break the immune system’s tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza.

The company is involved in conducting and planning clinical programs of its proprietary SynCon immunotherapies for HPV-caused pre-cancers and cancers; prostate, breast, lung, and pancreatic cancers; hepatitis C virus; hepatitis B virus; human immunodeficiency virus; Ebola virus; middle east respiratory syndrome; and Zika virus.

The context right now for the stock is a bit of a bid, with shares acting well over the past five days, up about 4% in that timeframe.

Inovio Pharmaceuticals Inc (NASDAQ:INO) pulled in sales of $867K in its last reported quarterly financials, representing top line growth of -56.7%. In addition, the company has a strong balance sheet, with cash levels far exceeding current liabilities ($93.8M against $19.5M).

 

Alpha Pro Tech, Ltd. (NYSEAMERICAN:APT) engages in developing, manufacturing, and marketing a line of disposable protective apparel, building supply products, and infection control products in the United States and internationally.

The big idea powering the stock lately is its products of masks capable of helping to prevent the spread of COVID-19.

The company operates through three segments: Building Supply, Disposable Protective Apparel, and Infection Control. The Building Supply segment offers construction weatherization products, such as house wrap, synthetic roof underlayment, and other woven materials.

The Disposable Protective Apparel segment provides shoe covers, bouffant caps, gowns, coveralls, lab coats, hoods, frocks, and other miscellaneous products.

The Infection Control segment offers face masks and eye shields. The company provides its products under the Alpha Pro Tech brand name, as well as under private labels. Its products are used primarily in cleanrooms; industrial safety manufacturing environments; health care facilities, such as hospitals, laboratories, and dental offices; pharmaceutical markets; and building and re-roofing sites.

The company distributes its products through a network of purchasing groups, distributors, and independent sales representatives, as well as through its sales and marketing force.

APT has had a rough past week of trading action, with shares sinking something like -29% in that time. That said, chart support is nearby and we may be in the process of constructing a nice setup for some movement back the other way. On a larger timeframe, the stock has been a juggernaut in the wake of news surrounding the COVID-19 outbreak, up as much as 1000% in the past 2 months.

Alpha Pro Tech, Ltd. (NYSEAMERICAN:APT) managed to rope in revenues totaling $10.9M in overall sales during the company’s most recently reported quarterly financial data — a figure that represents a rate of top line growth of -0.4%, as compared to year-ago data in comparable terms. In addition, the company has a strong balance sheet, with cash levels far exceeding current liabilities ($6.9M against $2.3M).

 

Co-Diagnostics Inc (NASDAQ:CODX) promulgates itself as a molecular diagnostics company that intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules. It also intends to sell diagnostic equipment from other manufacturers as self-contained lab systems.

The stock has been on a rampage for a simple reason: it has an inside track as a key distributor in the extremely important process of testing for COVID-19 infections in the US and international markets. As the outbreak expands, which it will, testing will be as important as anything else in regaining control.

And the stock has been acting well over recent days, up something like 10% in that time.

Co-Diagnostics Inc (NASDAQ:CODX) generated sales of $41K, according to information released in the company’s most recent quarterly financial report. That adds up to a sequential quarter-over-quarter growth rate of -32.7% on the top line. In addition, the company has a strong balance sheet, with cash levels far exceeding current liabilities ($2.5M against $308K).

 

Sugarmade Inc (OTCMKTS:SGMD) is especially interesting here because of the nesting trend among consumers. SGMD recently took a major stake in BudCars, with the contractual option to gain a controlling interest in the leading California cannabis delivery business.

This morning, the company announced a sharp rise in demand for its cannabis delivery service, driving an associated 10% week-over-week rise in total sales, over the past two weeks. According to the release, the company believes this dynamic is being driven by the stay-at-home trend that has emerged in many communities around the world in response to the global pandemic outbreak of the COVID-19 disease.

BudCars is undertaking an expansion in headcount to meet the current and anticipated sharp expansion in demand. SGMD now anticipates the upward shift in sales growth to help solidify its $15 million 2020 revenue target as a conservative target for sales this year.

“The Coronavirus pandemic is undeniably a game-changer for consumer behavior patterns that will likely have long-term implications as it drives new habits into place,” commented Jimmy Chan, CEO of Sugarmade, who recently announced a large stake in BudCars with an option for a controlling stake. “As a growing mobile ecommerce and delivery service in one of the fastest growing commercial markets, BudCars is extremely well-positioned for this dynamic. It’s already very clear: people are showing an overwhelming preference toward delivery as nesting takes hold. That applies to cannabis as much as anything else. We are fully prepared for a continuous ramp in demand for our delivery services over coming months and beyond.”

On this basis, the stock appears massively underpriced because it hasn’t yet made the dramatic jump that other stocks in this list have already displayed.

With the stay-at-home dynamic now taking a vice-grip on consumers, and cannabis demand unlikely to wane in the process, SGMD could be poised for dramatic gains once the crowd finds it.

 

Ibio Inc (NYSEAMERICAN:IBIO) bills itself as a biotechnology company that provides product development and manufacturing services to clients, collaborators, and third-party customers in the United States and internationally.

The company’s services cover the stages of pre-clinical development, regulatory approval, commercial product launch, and on-going commercial phase requirements. Its lead therapeutic candidate is IBIO-CFB03 for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and other fibrotic diseases.

The company is also developing vaccine candidates for third parties. It has a license agreement with the University of Natural Resources and Life Sciences, Vienna; a strategic relationship with Beijing CC-Pharming Ltd.; and collaboration agreements with AzarGen Biotechnologies (Pty) Ltd, The Texas A&M University System, and Fraunhofer Center for Molecular Biotechnology.

In addition, the company offers a range of product and process development, analytical, and manufacturing services.

The stock has suffered a bit of late, with shares of IBIO taking a hit in recent action, down about -27% over the past week. But that move comes in the context of a 400% rally as the market fuels companies potentially instrumental in the battle against the COVID-19 threat.

Ibio Inc (NYSEAMERICAN:IBIO) pulled in sales of $314K in its last reported quarterly financials, representing top line growth of -51.8%. In addition, the company is battling some balance sheet hurdles, with cash levels struggling to keep up with current liabilities ($3.6M against $4.7M, respectively).

 

Aytu Bioscience Inc (NASDAQ:AYTU) bills itself as a specialty pharmaceutical company that focuses on developing and commercializing novel products in the field of hypogonadism (low testosterone), cough and upper respiratory symptoms, insomnia, and male infertility in the United States and internationally.

The company markets Natesto, a nasal gel for the treatment of hypogonadism (low testosterone) in men; and Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension. It also offers ZolpiMist, an oral spray for the treatment of insomnia; and MiOXSYS, an in vitro diagnostic semen analysis test that is used in the measurement of static oxidation reduction potential in human semen.

If you’re long this stock, then you’re liking how the stock has responded to the announcement. AYTU shares have been moving higher over the past week overall, pushing about 127% to the upside on above average trading volume.

Aytu Bioscience Inc (NASDAQ:AYTU) pulled in sales of $3.2M in its last reported quarterly financials, representing top line growth of 76.9%. In addition, the company is battling some balance sheet hurdles, with cash levels struggling to keep up with current liabilities ($5.5M against $15.9M, respectively).

Continue Reading

Business

The Future of Cannabis is All About Delivery (APHA, MMNFF, SGMD, UBER, ACB, TLRY, GRUB, AMZN)

Published

on

As the Cannabis space continues to mature as a legitimate commercial marketplace, there are a number of dynamics we can expect to appear and change the game. One, in particular, seems likely to offer investors a big opportunity: Delivery.

With mobile ordering, real-time geospatial tracking, and sophisticated logistical processes in place, developed in industries like supply chain management and food distribution, the infrastructure and knowledge capital is already developed for transportation into other industries for efficient deployment. And newly emerging consumer growth markets are the most obvious implementation.

Cannabis is already huge and it’s going to get a whole lot bigger as the legal obstacles are inexorably toppled over coming quarters and years. It’s just a matter of time before millions of people will be going to their mobile phones and tapping a pot-leaf symbol to open up an app and order some weed.

But there’s three ways it might go:

  1. Current leading players in the cannabis industry will develop effective delivery operations (or strategic relationships),
  2. Current leading players in the delivery industry will develop effective cannabis operations (or strategic relationships), or
  3. New companies will gain a dominant foothold by specializing in delivering cannabis.

Either way, this is likely to be a huge business and a defining opportunity for savvy investors in ahead of the game, and whoever gets into a leadership position will have a first-mover advantage.

With all of that in mind, we take a look here at some potential scenarios involving likely players in this theme over the near term: Aphria Inc (NYSE:APHA), Medmen Enterprises Inc (OTCMKTS:MMNFF), Sugarmade Inc (OTCMKTS:SGMD), Uber Technologies Inc (NYSE:UBER), Aurora Cannabis Inc (NYSE:ACB), Tilray Inc (NASDAQ:TLRY), GrubHub Inc (NYSE:GRUB), and Amazon.com, Inc. (NASDAQ:AMZN).

 

Aphria Inc (NYSE:APHA) commands a market cap of $908M as a leading global cannabis company driven by “an unrelenting commitment to our people, product quality and innovation.” The company has been a clear innovator and grown through strategic relationships in the past. Hence, it’s a decent candidate as a possible innovator willing to cultivate delivery operations, but we haven’t yet seen signs of it.

Headquartered in Leamington, Ontario – the greenhouse capital of Canada – Aphria has been setting the standard for the low-cost production of safe, clean and pure pharmaceutical-grade cannabis at scale, grown in the most natural conditions possible. Focusing on untapped opportunities and backed by the latest technologies, Aphria is committed to bringing breakthrough innovation to the global cannabis market.

The stock has suffered a bit of late, with shares of APHA taking a hit in recent action, down about -6% over the past week.

Aphria Inc (NYSE:APHA) managed to rope in revenues totaling $120.2M in overall sales during the company’s most recently reported quarterly financial data — a figure that represents a rate of top line growth of 454.5%, as compared to year-ago data in comparable terms. In addition, the company has a strong balance sheet, with cash levels far exceeding current liabilities ($497.7M against $152.5M).

 

Medmen Enterprises Inc (OTCMKTS:MMNFF), together with its subsidiaries, operates in the cannabis space in the United States, with a clear emphasis on the California market, where we already see some development in the cannabis delivery marketplace. But the company hasn’t yet found its way into this niche.

MMNFF, more broadly, is a leading cannabis company in the U.S. with assets and operations across the country. Based in Los Angeles, MedMen brings expertise and capital to the cannabis industry and is one of the nation’s largest financial supporters of progressive marijuana laws.

The company cultivates, produces, possesses, uses, and distributes/retails cannabis in the recreational and medicinal cannabis marketplace. As of June 6, 2018, it owned and operated 18 licensed cannabis facilities under the MedMen brand name in California, Nevada, and New York.

The company frames itself as “the preeminent cannabis company in the United States” with multiple assets and operations in California, Nevada, New York, and Florida. MedMen owns and operates licensed cannabis facilities in cultivation, manufacturing, and retail, and is one of the most well-recognized cannabis brands in the world today.

The Company is the single largest financial supporter of progressive marijuana laws at the local, state and federal levels, giving directly to pro-legalization groups, industry organizations and political candidates.

Overall, MedMen has been mired in legal issues already and seems unlikely to take the strategic risks necessary to gain a foothold in the emerging delivery opportunity.

 

Sugarmade Inc (OTCMKTS:SGMD) is perhaps the most interesting stock on this list because the company is the only name that is already doing this. SGMD is a cannabis company that just took a major controlling interest in Budcars, a leading cannabis deliver company in the Sacramento area.

Sugarmade says it is focused on vertically integrating the theme, cultivating, marketing, and delivering cannabis to customers in northern California.

To that end, the company just announced a dramatic 300 percent sequential monthly jump in delivery volume in BudCars in February.

According to its release, the rise in volume follows the Company’s negotiated agreement toward a controlling stake in Budcars and its investment in expanding the leading delivery service’s operations and reach in Northern California. Management now projects a Budcars top-line run-rate capable of surpassing $15 million in sales in 2020, provided recent data on growth in daily orders is reliable and indicative of the impact of the Company’s recent measures over coming months.

As noted above, the Company has negotiated a 40 percent stake in Budcars with a provisional option to assume a controlling ownership position through the acquisition of an additional 30 percent stake.

“Some of our shareholders have suggested that our vision for a massively expanded and vertically integrated Budcars might be explained to the world as the ‘Uber Eats of the cannabis market.’ But we believe that’s actually a dramatic underestimation of where Budcars is headed,” remarked Jimmy Chan, CEO of Sugarmade. “This is far more promising from a bottom-line perspective, given that we aren’t simply delivering someone else’s product. The retailer gets the juicy 20 percent net margin in this business. We are positioning ourselves as a ‘Cannabis concierge service’ focusing on a truly unique cannabis experience.”

Across the board right now, SGMD is probably the most obvious candidate to take the early lead in this cannabis deliver theme.

 

Uber Technologies Inc (NYSE:UBER) bills itself as a company that develops and supports proprietary technology applications that enable independent providers of ridesharing, and meal preparation and delivery services to transact with end-users worldwide.

The company operates in two segments, Core Platform and Other Bets. Its driver partners provide ridesharing services through a range of vehicles, such as cars, auto rickshaws, motorbikes, minibuses, or taxis, as well as based on the number of riders under the UberBLACK, UberX, UberPOOL, Express POOL, and Uber Bus names; and restaurant and delivery partners provide meal preparation and delivery services under the Uber Eats name.

The company’s move into the Uber Eats division is a clear precursor to the core premise of delivering consumer goods like cannabis. But the brand management idea is important here as well. It may happen – if it does at all – as a stealth investment in a new startup that is geared toward this theme.

However, one major drawback for this model is that the company would only be capturing the fee for delivery, and volume in cannabis isn’t likely to be enough to make a major difference in its numbers for the markets. The real point here is the margins available in the cannabis space. And mere delivery fees just don’t match up well in that analysis.

Uber Technologies Inc (NYSE:UBER) generated sales of $4.1B, according to information released in the company’s most recent quarterly financial report. That adds up to a sequential quarter-over-quarter growth rate of 6.7% on the top line. In addition, the company has a strong balance sheet, with cash levels far exceeding current liabilities ($11.4B against $5.6B).

 

Aurora Cannabis Inc (NYSE:ACB) is one of the most widely diversified players in the cannabis space due to its powerful strategic investments.

In addition, the company has demonstrated rapid organic growth and strong execution on strategic M&A, which to date includes 15 companies – MedReleaf, CanvasRX, Peloton Pharmaceutical,  Aurora Deutschland (formerly Pedanios), H2 Biopharma, Urban Cultivator, BC Northern Lights, Larssen Greenhouses, CanniMed Therapeutics, Anandia Labs, HotHouse Consulting, Agropro, Borela, and the pending acquisition of ICC Labs.

We would expect expansion on the way given the inflow of investment capital. But, at present, the Company operates a 55,200 square foot, state-of-the-art production facility in Mountain View County, Alberta, known as Aurora Mountain, is currently constructing a second 800,000 square foot production facility, known as “Aurora Sky”, at the Edmonton International Airport, and has acquired, and is undertaking completion of a third 40,000 square foot production facility in Pointe-Claire, Quebec, on Montreal’s West Island.

While this is a clear factor, it has been incorporated into a trading tape characterized by a pretty dominant offer, which hasn’t been the type of action ACB shareholders really want to see. In total, over the past five days, shares of the stock have dropped by roughly -9% on above average trading volume. All in all, not a particularly friendly tape, but one that may ultimately present some new opportunities.

Aurora Cannabis Inc (NYSE:ACB) generated sales of $56M, according to information released in the company’s most recent quarterly financial report. That adds up to a sequential quarter-over-quarter growth rate of -25.5% on the top line. In addition, the company has a strong balance sheet, with cash levels far exceeding current liabilities ($227.5M against $213.9M).


Tilray Inc (NASDAQ:TLRY)
engages in the research, cultivation, processing, and distribution of medical cannabis.

The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. was incorporated in 2018 and is headquartered in Nanaimo, Canada.

One of its key subsidiaries is High Park, which was launched to produce and distribute world-class cannabis brands and products for the Canadian market. Based in Toronto and led by a team with deep experience in cannabis and global consumer brands, High Park has secured the exclusive rights to produce and distribute a broad-based portfolio of cannabis brands and products in Canada, subject to applicable laws and regulations.

TLRY has had a rough past week of trading action, with shares sinking something like -21% in that time. That said, chart support is nearby and we may be in the process of constructing a nice setup for some movement back the other way.

Tilray Inc (NASDAQ:TLRY) pulled in sales of $51.1M in its last reported quarterly financials, representing top line growth of 408.6%. In addition, the company is battling some balance sheet hurdles, with cash levels struggling to keep up with current liabilities ($122.4M against $130.2M, respectively).

This is not a well-run company and its debt-servicing burden alone makes it extremely unlikely to ever be able to forge into new and innovative directions. So, taking a lead in captaining the cannabis delivery market on a mainstream basis is out of the question.

 

GrubHub Inc (NYSE:GRUB) trumpets itself as a company that provides an online and mobile platform for restaurant pick-up and delivery orders in the United States.

The company connects approximately 105,000 local restaurants with diners with diners in various cities. It offers Grubhub, Seamless, and Eat24 mobile applications and mobile Websites; and operates Websites through grubhub.com, seamless.com, eat24.com, and menupages.com.

The company also provides corporate program that offers employees with various food and ordering options, including options for individual meals, group ordering, and catering, as well as proprietary tools that consolidate various food ordering into a single online account. In addition, it offers Allmenus.com and MenuPages.com, which provide an aggregated database of approximately 440,000 menus from restaurants in 50 U.S. states; Grubhub for Restaurants, a responsive Web application that can be accessed from computers and mobile devices, as well as Grubhub-provided tablets; point of sale (POS) integration, which allows restaurants to manage Grubhub orders and update their menus directly from their existing POS system; and Website and mobile application design and hosting services for restaurants, as well as technology and fulfillment services, including order transmission and customer relationship management tools.

And the stock has been acting well over recent days, up something like 7% in that time. Over the past month, shares of the stock have suffered from clear selling pressure, dropping by roughly -6%.

GrubHub Inc (NYSE:GRUB) generated sales of $341.3M, according to information released in the company’s most recent quarterly financial report. That adds up to a sequential quarter-over-quarter growth rate of 6% on the top line. In addition, the company has a strong balance sheet, with cash levels far exceeding current liabilities ($425.7M against $249.4M).

 

Amazon.com, Inc. (NASDAQ:AMZN) is another obvious player in this narrative. The company takes over every industry at some point. Next it will probably be Amazon Oil Company or Amazon Airlines. Will they eventually move into cannabis? Only time will tell.

We put them here because they have the history of innovation and creeping horizontality to suggest it isn’t impossible, and they also certainly know how to drive commerce through delivery.

It will be interesting to see if the stock can break out of its recent sideways action. Over the past week, the stock is net flat, and looking for something new to spark things. Over the past month, shares of the stock have suffered from clear selling pressure, dropping by roughly -4%. But that’s pretty good considering the Nasdaq is down 10% in the same period.

Amazon.com, Inc. (NASDAQ:AMZN) pulled in sales of $87.4B in its last reported quarterly financials, representing top line growth of 20.8%. In addition, the company is battling some balance sheet hurdles, with cash levels struggling to keep up with current liabilities ($55.3B against $87.8B, respectively).

Continue Reading

TRENDING

GB Sciences Inc (OTCMKTS:GBLX)’s PD Formulations Show Positive Effect In Reducing Behavioral Changes In Patients Suffering From Dopamine Producing Neurons Loss

Published

on

GB Sciences Inc (OTCMKTS:GBLX) is encouraged by the PD (Parkinson’s disease) formulations effect on patients suffering from the loss of dopamine-producing neurons. Halifax based NRC’s Dr. Lee Ellis is performing the study using the PD formulations of GB Sciences on people suffering from low levels of dopamine-producing neurons. The company will conduct the final study on the mechanism of action using these PD formulations that help to provide relief for patients.

Human clinical trial begins next year

Director and Chief Scientific Officer of GB Sciences, Dr. Andrea Small-Howard, said the mixtures of GB Sciences are effective. Its most effective mixture has shown positive results in reducing the behavioral changes and brings back to the normal level when tests are conducted on animals. According to CSO, the PD formulation has shown almost negligible side effects. The company will include these preclinical results as a proof of concept when applying for investigational new drug application with the FDA. Following the nod of the US FDA, GB Sciences will begin a human clinical trial next year.

Reduced dopamine levels cause movement disorders

Reduced dopamine levels in the brain are responsible for movement disorders. The PD formulations, developed by GB Sciences, will protect the dopamine-producing neurons. It will activate the surviving to increase secretion of dopamine and compensates for the reduction in dopamine-producing neurons. The company will examine these effects of PD formulation in the final study.

Director and President of GB Sciences, Dr. Michael Farley, said positive preclinical trial shows CBD containing complex mixtures expect to cure Parkinson’s disease symptomology. He further said the company would conduct the human clinical trials using these effective PD formulations in 2020.

Signs a binding LOI to sell membership interests

GB Sciences has signed a binding LOI to divest 75% of the membership interests in its Las Vegas, Nevada production operation, and cultivation. Following the deal, GB Sciences will reduce its operational spending and produce working capital. It will also generate sufficient cash flow to concentrate on wellness and biopharmaceutical assets. Following this deal, GB Sciences will exit from cannabis production and cultivation. The company will receive $6 million that includes $3 million in cash and the balance promissory note.

Continue Reading
Advertisement

Whats Hot